The Armchair Analyst

The Armchair Analyst

5-minute daily updates on the ASX life-sciences sector.

Recent Articles

Trust Your Gut: The Microba (ASX: MAP) Story

Trust Your Gut: The Microba (ASX: MAP) Story

Mar 6, 2026

•

13 min read

The M&A Slide Just Updated Itself: $1.5 billion deal

The M&A Slide Just Updated Itself: $1.5 billion deal

Mar 5, 2026

•

5 min read

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Three Shots, One Strategy: The Syntara (ASX: SNT) Story

Mar 4, 2026

•

12 min read

Risk On, Risk Off: Understanding the Market’s Rhythm

Risk On, Risk Off: Understanding the Market’s Rhythm

Mar 2, 2026

•

6 min read

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

A US-First Strategy for Ovarian Cancer Screening: The Cleo (ASX: COV) story

Feb 27, 2026

•

14 min read

Half-Yearlys are out. Score Check?

Half-Yearlys are out. Score Check?

Feb 26, 2026

•

7 min read

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Climbing the Diagnostics Mount Everest: The BCAL (ASX: BDX) Story

Feb 25, 2026

•

17 min read

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

CAR-T Cell Therapies back on the menu with $7.8 billion acquisition

Feb 24, 2026

•

6 min read

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Sprinting to the starting line: The Rhythm Biosciences (ASX: RHY) Story

Feb 23, 2026

•

13 min read

The Three-Day Market Update

The Three-Day Market Update

Feb 20, 2026

•

10 min read

The Price of Buying Time: The Adherium (ASX: ADR) Story

The Price of Buying Time: The Adherium (ASX: ADR) Story

Feb 17, 2026

•

12 min read

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

The Path to Blue-Chip: The Clarity Pharmaceuticals (ASX: CU6) Story

Feb 16, 2026

•

13 min read

...